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Background: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma
(DLBCL) by ~20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas,
is the target for rituximab. The goal of our study was to examine polymorphism in the CD20 gene in Chinese
DLBCL population and whether CD20 gene polymorphism is associated with clinical response to R-CHOP.
Method: CD20 gene polymorphism was detected in the entire coding regions including 6 exons by polymerase
chain reaction (PCR)-sequencing assay in 164 patients with DLBCL. Among them, 129 patients treated with R-CHOP
as frontline therapy (R ≥ 4 cycles) were assessable for the efficacy.
Results: Polymorphisms at three single nucleotides (SNP) were identified in the entire coding regions of the CD20
gene in the 164 patients. One of them, CD20 Exon2 [216] was found to be highly correlated with response to R-
CHOP. Patients with homozygous C genotype showed a trend toward higher overall response rate than others with
CT plus TT genotype (90.6% vs. 79.5%; P =0.166). A trend toward higher complete remission (CR) rate was observed
in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).
Conclusion: These results suggest that there are 3 SNPs in CDS of the CD20 gene in Chinese DLBCL population.
The CC genotype at Exon2 [216] appears to be associated with favourable response to R-CHOP.Introduction
Genetic polymorphisms are variants in individual genomes
and remain constant throughout a person’s lifetime. Many
genetic polymorphisms contribute to variability in drug
pharmacokinetic and pharmacodynamic processes [1]. The
relationship between therapeutic efficacy and gene poly-
morphism has been extensively studied for a few monoclo-
nal antibodies [2,3].
Rituximab is a chimeric monoclonal antibody targeting
the CD20 antigen on normal and neoplastic B cells
[4-7]. R-CHOP (rituximab, cyclophosphamide, doxo-
rubicin, vincristine and prednisone) has significantly* Correspondence: songyuqin622@sina.com; zj@bjcancer.org
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reproduction in any medium, provided the orimproved survival rates of patients with diffuse large B
cell lymphoma (DLBCL) [8-11]. CD19 and other mono-
clonal antibodies are also being explored for novel
lymphoma therapies [12].
CD20 was first identified as a B-cell specific marker in
1980 [13], which was highly expressed on more than
80% of B-cell lymphomas but not on stem cells, pro-B
cells, normal plasma cells, or other normal tissues [14].
The CD20 gene, namely MS4A1 gene, is located on
chromosome 11q12-q13.1 with 6 exons in its coding se-
quence (CDS) [15,16]. To date, 509 single-nucleotide
polymorphisms (SNPs) have been reported for the CD20
gene. Among them, 57 SNPs are located in CDS, but
there were no genotype and allele frequency data for
most SNPs. In particular, there has been no report on
the relationship between CD20 gene SNPs and their im-
pacts on the response to R-CHOP in DLBCL patients.
Several clinical studies offered scanty information aboutd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CD20 mutations in tumour tissues. Johnson et al. de-
scribed that the CD20 gene mutations in the rituximab
epitope are rare and no SNPs were detected in exon 5 of
the CD20 gene [17]. Another study found no mutation
in the CDS of the CD20 gene in tumours from 23 pa-
tients, with only one case showing a SNP [16].
Therefore, this study examined polymorphism of the
CD20 gene in Chinese DLBCL population and the rela-
tionship between the polymorphism and clinical efficacy
in patients with DLBCL treated with R-CHOP.
Methods
Study population
The clinical research protocol had been approved by our
Institutional Review Board (IRB). This study had been
approved by the Research and Ethical Committee of
Peking University School of Oncology. A written in-
formed consent had been obtained from each patient
participated in this study.
This study included 164 patients with CD20+ DLBCL
confirmed by our Department of Pathology according to
the World Health Organization classification. All pa-
tients received R-CHOP (120 patients) or R-CHOP-like
(44 patients) chemotherapy regimen between June 2007
and December 2010 at Beijing Cancer Hospital, Peking
University School of Oncology. For elderly patients or
patients with other complications, the dosage of CHOP
was changed, which is not standard dosage of CHOP, so
called R-CHOP-like. R-CHOP chemotherapy was admin-
istered as follows: one course of chemotherapy consisted
of an intravenous infusion of Cyclophosphamide
750 mg/m2, adriamycin 50 mg/m2, vincristine 2 mg, and
an oral administration of 100 mg prednisone on days 1
to 5, which was repeated every 3 weeks. Rituximab
375 mg/m2 was infused over 4 to 6 hours on day 1 be-
fore CHOP or CHOP-like chemotherapy was started.
Among the 164 patients, 129 received frontline R-CHOP
and were evaluable for clinical efficacy. Of the 129 pa-
tients, 31 patients received involved-field radiation. The
response to R-CHOP therapy was evaluated after com-
pletion of 2 to 3 courses of therapy and 1 to 2 months
after completion of all therapy plans, then every
3 months for the first year and every 6 months thereafter
until progression.
Analysis of the CD20 gene polymorphisms
Blood samples were obtained from all lymphoma pa-
tients before the initiation of therapy for genetic analysis.
Genomic DNA was prepared from peripheral-blood
mononuclear cells using Blood Genomic DNA extrac-
tion kit following the manufacturer’s instructions
(Bioteke Corporation, China). All 6 exons of the CD20
gene were examined by polymerase chain reaction(PCR)-sequencing assay. Genomic DNA (30 ng per 30 μl
reaction) was amplified with GoTaq DNA polymerase
(Promega Cor., WI, USA) and exon-specific primer sets
for each of the 6 exons [12]. PCR reaction conditions
were programmed on a thermo cycler (Gene Cycler TM,
Bio-Rad, CA, USA) as follows: denaturation at 94°C for
5 min, followed by 35 cycles of 94°C for 30s, 56°C for
30 s, 72°C for 45 s. The last cycle was followed by 72°C
for 7 min. Amplified products were analyzed by gel
electrophoresis on 2% agarose gels. All fragments were
purified with the AxyPrep DNA Gel Extraction kit
according to the manufacturer’s instructions (Axygen
Sci. Inc., CA, USA). Those purified products were se-
quenced using an ABI 3730XL Avant Genetic Analyzer
(Applied Biosystems Inc., CA, USA). Finally, the se-
quences were analyzed with the software Seqman
(DNASTAR Inc., WI, USA).
Definitions
The patients who had heterozygous (CT) or homozy-
gous T (TT) genotype of CD20 Exon2[216] were desig-
nated as T carriers. Clinical responses were scored with
the criteria formulated by International Working Group
[18] and were determined by physical examination and
confirmed by computed tomography or ultrasound. The
latter was only used for evaluating superficial lymph
nodes. Disease specific survival (DSS) was calculated as
the day 1 of the first cycle of R-CHOP until death for
DLBCL, or until the last follow-up available. The
progression-free survival (PFS) was calculated from day
1 of the first cycle of R-CHOP until disease progression,
or death for any cause. If a patient had not progressed
or died, PFS was censored at the time of last follow-up.
Statistical analysis
The clinical characteristics and response rate of the pa-
tients were compared using χ2 test and Fisher’s Exact
Test according to the CD20 SNP. The association of
polymorphism with DSS and PFS was analyzed using
Kaplan-Meier curves and the log-rank test. The prog-
nostic factors were evaluated by the Cox regression
model. Differences between groups were regarded as sig-
nificant with a P < 0.05. All tests of statistical significance




The general features of the patients in this study are
summarized in Table 1, including 81 female and 83
male. The median age at diagnosis was 53 years (range,
15–90 years). Eighty nine (54%) patients were in stages 3
or 4 and 50 (30%) patients had intermediate-to-high or
high International Prognostic Index (IPI) scores. Bone
Table 1 Patient’s characteristics and their correlations with CD20 Exon2[216] genotype
Clinical
parameters
No. Genotype P* Clinical
parameters
No. Genotype P*
CC CTplusTT CC CTplusTT
Gender Bulky mass
Male 83 63 20 0.787 ≥10cm 18 11 7 0.249
Female 81 60 21 <10cm 146 112 34
Age Localized
≤60 102 76 26 0.852 Yes 25 19 6 0.900
>60 62 47 15 No 139 104 35
B symptoms No Extra Nodal
Positive 62 46 16 0.852 ≤1 122 90 32 0.535
Negative 102 77 25 >1 42 33 9
LDH Incidence site
Positive 77 55 22 0.320 Lymph node 93 68 25 0.524
Negative 87 68 19 Extralymph 71 55 16
β2-MG IPI
Positive 49 35 14 0.684 0-2 114 84 30 0.557
Negative 106 79 27 3-5 50 39 11
Stage Molecular subtypes
I-II 75 55 20 0.651 GCB 28 21 7 0.868
III-IV 89 68 21 Non-GCB 113 83 30
Abbreviations: LDH lactate dehydrogenase level, MG macroglobulin, IPI international prognostic index, GCB germinal centre B cell, *χ2 test.
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diagnosis. R-CHOP followed by involved-field radiation
was given to 31 (19%) patients. R-CHOP as a front-line
regimen was administrated to 129 patients whose clin-
ical efficacy was evaluable for this study. A median of 6
rituximab doses were given (range, 4–14), and a median
of 6 cycles of chemotherapy was given (range, 2–
8 cycles).
CD20 gene polymorphism
Three SNPs were identified in the entire coding regions
(6 exons) of the CD20 gene in this DLBCL patient popula-
tion (Table 2). All three SNPs were located in exon1 and
exon2. Exon 3–6 showed no SNPs. The c.111G > C in
exon 1, the c.208C > T and c.216C > T (CD20 Exon2[216])
in exon2 have been previously reported separately as
rs200805059, rs79703274 and rs2070770 (www.ncbi.nlm.Table 2 CD20 polymorphisms in 164 Chinese people with
DLBCL
Nucleotide change* Effect on protein location Ref
c.111G > C p.L37L Exon1 rs200805059
c.208C > T p.L70L Exon2 rs79703274
c.216C > T p.I72I Exon2 rs2070770
Abbreviations: G Guanine, C Cytosine, T Thymine, L Leu, leucine, I:Ile isoleucine.
* Position in CD20 cDNA is according to Reference Sequence: NM_021950.3.
The mutation nomenelature follows the instructions provided by the HGVS
(http://www.hgvs.org). The DNA polymorphisms numbering is based on cDNA
sequence with +1 corresponding to the A of the ATG translation
initiation codon.nih.gov/SNP/snp_ref.cgi?locusId=931). Genotype and al-
lele frequencies of the CD20 gene polymorphism in 164
patients with DLBCL were analyzed (Table 3). The fre-
quency of the CD20 Exon2 [216] C allele among the 164
patients was 0.869, whereas the frequency of the CD20
Exon2[216] T allele was 0.131. Seventy-five percent (123 of
164) of patients were homozygous for CD20 Exon2[216] C
allele, 23.8% (39 of 164) were heterozygous (C/T), and
1.2% (2 of 164) were homozygous for CD20 Exon2[216] T
allele (Table 3). The genotype distribution of DLBCL
population enrolled in this study was in Hardy-Weinberg
equilibrium with regard to the CD20 Exon2[216] poly-
morphism examined (P = 0.57).
Patient characteristics according to Exon2[216] allele status
There was no significant difference in patients’ disease
features between the CD20 Exon2[216] CC and CT plus
TT polymorphism groups (Table 1).
Clinical responses and Exon2 [216] Polymorphism
Although not statistically significant, the patients with
homozygous C genotype showed a trend toward higher
overall response rate than those with CT plus TT geno-
type (90.6% vs. 79.5%; P =0.166, Table 4). The trend
seems to be largely due to a better complete response
rate (CR). Higher CR rate was observed in patients with
homozygous C genotype (67.4%) compared to those with
CT plus TT genotype (47.1%) (P = 0.091). When the rate
of CR was compared with that of non-CR (PR + SD +
Table 3 Genotype and allele frequencies of CD20 polymorphisms in 164 Chinese patients with DLBCL
SNP
Genotype frequencies Allele frequencies
Genotype freq count Genotype freq count Genotype freq count Total Allele freq count Allele freq count Total
c.111G>C GG 0.988 162 GC 0.012 2 CC 0 0 164 G 0.994 326 C 0.006 2 328
c.208C>T CC 0.994 163 CT 0.006 1 TT 0 0 164 C 0.997 327 T 0.003 1 328
c.216C>T CC 0.750 123 CT 0.238 39 TT 0.012 2 164 C 0.869 285 T 0.131 43 328
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of the homozygous C genotype (χ2, 4.384; P = 0.036)
(Table 4). When the patients were subdivided into GCB
and non-GCB lymphoma groups, the better response
rate was observed in non-GCB groups (59.0% vs. 37.5%;
P =0.074), not in GCB (80.0% vs. 71.4%; P =0.633).
Survival analysis according to CD20 Exon2[216] genotype
After a median follow-up time of 524 days (range, 60–
2073 days), 32 (25%) patients relapsed or progressed,
and 18 (14%) died. Seven patients participated in a clin-
ical trial evaluating everolimus (RAD001) and were cen-
sored for PFS analysis. The patients with homozygous C
genotype had a median PFS of 465 days (range, 50–
1275 days) versus 442 days (range, 41–1255 days) for the
rests, but the difference did not reach statistical signifi-
cance (P = 0.204) (Figure 1). Survival data was available
for 123 patients. Six patients were censored for not
being died of DLBCL. The DSS was 536 days (range,
143–1364 days) for homozygous C patients, and 571 days
(range, 142–1350 days) for T carriers (P = 0.316,
Figure 2). This difference was neither statistically signifi-
cant between GCB and non-GCB lymphoma groups
(data not shown).
Multivariate analysis
A multivariate analysis was done to evaluate the follow-
ing variables on DSS and PFS: age (≤60 vs. >60 years),
stage (stages 1,2 vs. 3,4), B symptoms (positive vs.Table 4 Clinical response to R-CHOP therapy according to
CD20 Exon2[216] Polymorphism
Response CD20 exon2[216] genotype n (%) P
Value*CC No.(%) CT + TT No.(%)
No.(N = 129) 95 34
CR 64(67.4) 16(47.1) 0.091
PR 22(23.2) 11(32.4)
SD/PD 9(9.4) 7(20.5)
ORR(CR + PR) 86(90.6) 27(79.5) 0.166#1
CR 64(67.4) 16(47.1) 0.036#2
Non-CR 31(32.6) 18(52.9)
Abbreviations: CR complete response, PR partial response, SD stable disease, PD
progressive disease, ORR (OR + PR), overall response, non-CR, PR + SD + PD.
#1 P = 0.166 when comparing ORR with SD/PD;#2 P = 0.036 when comparing
CR with non-CR (PR + SD + PD) ;* χ2 test.negative), β2-microglobulin level (normal vs. abnormal),
LDH (normal vs. abnormal), IPI score (0–2 vs. 3–5), No.
of extra nodal sites (≤1 site vs. ≥2 sites), bulky mass
(≥10 cm vs. <10 cm), and Exon2[216] (homozygous C vs.
T carriers). This analysis confirmed that LDH (P = 0.034,
HR 4.23, 95% CI 1.113-16.057) was poor prognostic
factor.
Discussion
The focus of several previous study is on relationship of
mutations or/and polymorphisms of CD20 gene with the
response to R-CHOP in diffuse large B cell lymphoma
patients. However, in Sar’ study, the sample number is
less. Specimens are from 23 patients diagnosed with
DLBCL and treated with R-CHOP were included in the
study [16]. In Johnson’ study, only mutations or/and
polymorphisms in exon5 of CD20 gene were determined
[17]. In our study, all 6 exons of the CD20 gene were ex-
amined. Specimens are from 164 patients diagnosed with
DLBCL and treated with R-CHOP were included in our
study. This study described polymorphism in CD20
exons in Chinese DLBCL patient population for the first
time. There totally are 3 SNPs in CDS of the CD20 gene
in this population (Table 2). For population diversity,
there are still no genotype and allele frequency data
about the c.111G > C (rs200805059) and the c.208C > T
(rs79703274) in the NCBI SNP database prior to this
study. Here we obtained the genotype frequencies and
allele frequencies for above two SNPs in Chinese DLBCL
patient population (Table 3). C allele of c.111G > C and
T allele of c.208C > T are rare in this population. For the
c.216C > T (CD20 Exon2[216], rs2070770 ) the genotype
and allele distribution in DLBCL population from NCBI
SNP database was similar to those obtained from Han
Chinese in Beijing, China (Table 3). Thus, the overall al-
lelic distribution in Chinese DLBCL patients was not
statistically different from the allelic distribution in other
populations. In addition, the DLBCL population enrolled
in this study was in Hardy-Weinberg equilibrium with
regard to the CD20 Exon2[216]. More importantly, the
results described above provide first evidence that the
genetic polymorphism, CD20 Exon2[216] may have an
impact on clinical efficacy of R-CHOP (Table 4).
Several possible explanations for our findings can be
provided. CD20 is highly expressed on more than 80% of
the B-cell lymphomas [19]. The previous study suggested
Figure 1 Progression-free survival (PFS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of PFS was plotted by
CD20 Exon2 [216] CC and CT plus TT genotype.
Figure 2 Disease specific survival (DSS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of DSS was plotted by
CD20 Exon2 [216] CC and CT plus TT genotype.
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sion level of CD20 antigen, which may be related to the
resistance after rituximab therapy [20]. Therefore the
CD20 Exon2[216] may potentially alter the level of CD20
antigen expression, thus affecting the clinical response
to R-CHOP. We have used immunohistochemical
method (IHC) to detect correlation of CD20 expression
intensity with CD20 Exon2 [216], no significant difference
was found (Data was not shown). The CD20 Exon2[216]
C for T substitution is a synonymous SNP of the third
base of the codon for Ile72. Because synonymous SNPs
encode a change in the DNA sequence without altering
the resultant protein sequence, such “silent” changes
were long assumed to be inconsequential. However,
there is clear and accumulating evidence from recent
work that synonymous SNPs can alter the expression,
conformation, or function of a protein by a variety of
mechanisms, including altering the efficiency of gene
translation, affecting the stability of mRNAs and regulat-
ing the splicing process of mRNAs [21]. For example, a
synonymous SNP, the C3435T polymorphism in the
Multidrug Resistance 1(MDR1) gene affects MDR1 gene
product pP-glycoprotein (P-gp) activity through altering
its conformation [18,22]. Synonymous SNPs within the
DRD2 transcript can reduce the stability of the mRNA
and thus the expression of the dopamine receptor [23].
Synonymous SNPs in CHRNA4 alter the receptor re-
sponse to Ach [24]. To date, silent SNPs have been
reported in association with more than 40 diseases that
have genetic bases [25]. Meanwhile, according to biased
codon usage, synonymous SNP substituting a rare codon
for a common codon encoding the same amino acid
may directly impact the translation kinetics of a protein,
resulting in its function alteration [22,26]. In the case of
CD20 Exon2[216], the ATT > ATC transversion repre-
sents a change from a rare (ATT, 13.0 per thousand)
codon encoding isoleucine to a more frequently used
codon (ATC, 29.9 per thousand; frequencies obtained
from the Codon Usage Database:http://www.kazusa.or.
jp/codon/). Alternatively, CD20 Exon2[216] may be com-
monly inherited as part of a haplotype and exist in
linkage disequilibrium with other disease-associated mo-
lecular markers [20], such as SNPs from a key gene
involved in ADCC or cell-dependent cellular cytotoxicity
(CDCC).
While we explored a correlation between clinical out-
come and CD20 Exon2 [216], we found there are no statis-
tically significant correlation between CD20 Exon2[216]
genotypes and PFS and DSS (Figures 1 and 2). In addition,
the CD20 Exon2[216] was not an independent predictor for
prognosis. The possible explanation is that as a target,
CD20 antigen is an important factor for initial response,
but not for duration of R-CHOP response in DLBCL pa-
tients. The latter has different mechanisms and may bemore dependent on immunity status of DLBCL patients.
Meanwhile, patients with DLBCL, GCB lymphoma have
better survival than non-GCB lymphoma. In our study,
the difference of the overall survival between homozygous
C patients, and T carriers did not reach statistical signifi-
cance. This difference was neither statistically significant
between GCB and non-GCB lymphoma groups in sub-
group analysis (data not shown). Maybe it is a prognostic
factor independent of molecular subtypes (GCB or non-
GCB). Or it is possible that this may be due to the small
number of patients that preclude reliable analysis.
Conclusion
In conclusion, this study points to a possible association
between polymorphism in the CD20 gene and the re-
sponse to R-CHOP in DLBCL patients. Ongoing studies
will explore the impact of this SNP in a larger popula-
tion of DLBCL and verify it with laboratory experiment.
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